Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

Inclusion Criteria:

• Diagnosed with alopecia areata by either:
• A board-certified dermatologist, OR
• Dermatology Nurse Practitioner, OR
• Skin punch biopsy
• Patient has at least 2 alopecic patches each measuring at least 2 cm2 and are…
• Located on contralateral body sites OR
• Within the same body site but separated by ≥ 1 cm
• Patient is a candidate for intralesional triamcinolone.
• Patient able to give informed assent under IRB approval procedures when appropriate.
• At least one parent or guardian is able to provide informed consent.

Exclusion Criteria:

• Patient has alopecia totalis, alopecia universalis, or alopecia areata with ophiasispattern.
• Known allergy or hypersensitivity to triamcinolone acetonide
• Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4weeks after the study.
• Patient is unable/unwilling to provide informed assent when applicable.
• Known medical diagnosis or use of a medication that alters pain response at time ofinjection.
• Active infection at site designated for injection.
• If currently being treated for alopecia areata, the current treatment regimen has beenstarted within less than 4 weeks of screening.